202 related articles for article (PubMed ID: 33128485)
21. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
Okiyama N; Katz SI
J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
[TBL] [Abstract][Full Text] [Related]
22. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens.
Martin-Orozco N; Wang YH; Yagita H; Dong C
J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis.
Che YM; Zhang Y; Li M; Li XP; Zhang LL
J Cell Biochem; 2018 Apr; 119(4):3044-3057. PubMed ID: 29058791
[TBL] [Abstract][Full Text] [Related]
24. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
25. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
26. Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation.
Xu Z; Tsai HI; Xiao Y; Wu Y; Su D; Yang M; Zha H; Yan F; Liu X; Cheng F; Chen H
ACS Nano; 2020 Jul; 14(7):7959-7969. PubMed ID: 32515579
[TBL] [Abstract][Full Text] [Related]
27. IFN-γ treatment protocol for MHC-I
Stifter K; Krieger J; Ruths L; Gout J; Mulaw M; Lechel A; Kleger A; Seufferlein T; Wagner M; Schirmbeck R
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868392
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 on mast cells suppresses effector CD8
Hirano T; Honda T; Kanameishi S; Honda Y; Egawa G; Kitoh A; Nakajima S; Otsuka A; Nomura T; Dainichi T; Yaguchi T; Inozume T; Kataoka TR; Tamada K; Kabashima K
J Allergy Clin Immunol; 2021 Aug; 148(2):563-573.e7. PubMed ID: 33581199
[TBL] [Abstract][Full Text] [Related]
29. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
30. Control of Tumors by Antigen-Specific CD8
Feng PH; Wang X; Ferrall L; Wu TC; Hung CF
J Immunol Res; 2022; 2022():9054569. PubMed ID: 35028321
[TBL] [Abstract][Full Text] [Related]
31. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.
Keir ME; Freeman GJ; Sharpe AH
J Immunol; 2007 Oct; 179(8):5064-70. PubMed ID: 17911591
[TBL] [Abstract][Full Text] [Related]
32. Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model.
D'Anniballe VM; Huang MN; Lueck BD; Nicholson LT; McFatridge I; Gunn MD
J Immunother; 2023 Nov-Dec 01; 46(9):333-340. PubMed ID: 37737688
[TBL] [Abstract][Full Text] [Related]
33. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z; Hsu MA; Gicobi JK; Xu T; Harrington SM; Zhang H; Pavelko KD; Hirdler JB; Lohse CM; Nabavizadeh R; Pessoa RR; Sharma V; Thompson RH; Leibovich BC; Dong H; Lucien F
J Immunol; 2023 Jun; 210(12):2029-2037. PubMed ID: 37163328
[TBL] [Abstract][Full Text] [Related]
34. PD-1 signaling in neonates restrains CD8
Eddens T; Parks OB; Zhang Y; Manni ML; Casanova JL; Ogishi M; Williams JV
Mucosal Immunol; 2024 Jun; 17(3):476-490. PubMed ID: 38176655
[TBL] [Abstract][Full Text] [Related]
35. The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8
David P; Megger DA; Kaiser T; Werner T; Liu J; Chen L; Sitek B; Dittmer U; Zelinskyy G
Front Immunol; 2019; 10():54. PubMed ID: 30804928
[TBL] [Abstract][Full Text] [Related]
36. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
37. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
38. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
39. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology.
Hafalla JC; Claser C; Couper KN; Grau GE; Renia L; de Souza JB; Riley EM
PLoS Pathog; 2012 Feb; 8(2):e1002504. PubMed ID: 22319445
[TBL] [Abstract][Full Text] [Related]
40. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
